Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

33 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cooperative Armoring of CAR and TCR T Cells by T Cell-Restricted IL15 and IL21 Universally Enhances Solid Tumor Efficacy.
Nguyen R, Doubrovina E, Mousset CM, Jin BY, Okada R, Zhang X, Clavel A, Reyes-Gonzalez JM, Dyomin V, Diaz L, Zhang L, Abbas S, Sun M, Hsieh CM, Ho M, Shern JF, Gulley JL, Hinrichs CS. Nguyen R, et al. Among authors: doubrovina e. Clin Cancer Res. 2024 Apr 15;30(8):1555-1566. doi: 10.1158/1078-0432.CCR-23-1872. Clin Cancer Res. 2024. PMID: 37910044
Third-party cytomegalovirus-specific T cells improved survival in refractory cytomegalovirus viremia after hematopoietic transplant.
Prockop SE, Hasan A, Doubrovina E, Dahi PB, Rodriguez-Sanchez I, Curry M, Mauguen A, Papanicolaou GA, Su Y, Yao J, Arcila M, Boulad F, Castro-Malaspina H, Cho C, Curran KJ, Giralt S, Kernan NA, Koehne G, Jakubowski A, Papadopoulos E, Perales MA, Politikos I, Price K, Selvakumar A, Sauter CS, Tamari R, Vizconde T, Young JW, O'Reilly RJ. Prockop SE, et al. Among authors: doubrovina e. J Clin Invest. 2023 May 15;133(10):e165476. doi: 10.1172/JCI165476. J Clin Invest. 2023. PMID: 36951958 Free PMC article.
Phase I dose escalation safety and feasibility study of autologous WT1-sensitized T cells for the treatment of patients with recurrent ovarian cancer.
Kyi C, Doubrovina E, Zhou Q, Kravetz S, Iasonos A, Aghajanian C, Sabbatini P, Spriggs D, O'Reilly RJ, O'Cearbhaill RE. Kyi C, et al. Among authors: doubrovina e. J Immunother Cancer. 2021 Aug;9(8):e002752. doi: 10.1136/jitc-2021-002752. J Immunother Cancer. 2021. PMID: 34433633 Free PMC article. Clinical Trial.
Ocular Outcomes after Treatment of Cytomegalovirus Retinitis Using Adoptive Immunotherapy with Cytomegalovirus-Specific Cytotoxic T Lymphocytes.
Gupta MP, Koenig LR, Doubrovina E, Hasan A, Dahi PB, O'Reilly RJ, Koehne G, Orlin A, Chan RVP, D'Amico DJ, Park SS, Burkholder BM, Kiss S. Gupta MP, et al. Among authors: doubrovina e. Ophthalmol Retina. 2021 Sep;5(9):838-849. doi: 10.1016/j.oret.2021.04.009. Epub 2021 Apr 20. Ophthalmol Retina. 2021. PMID: 33892135 Free PMC article.
Epigenetic reprogramming sensitizes immunologically silent EBV+ lymphomas to virus-directed immunotherapy.
Dalton T, Doubrovina E, Pankov D, Reynolds R, Scholze H, Selvakumar A, Vizconde T, Savalia B, Dyomin V, Weigel C, Oakes CC, Alonso A, Elemento O, Pan H, Phillip JM, O'Reilly RJ, Gewurz BE, Cesarman E, Giulino-Roth L. Dalton T, et al. Among authors: doubrovina e. Blood. 2020 May 21;135(21):1870-1881. doi: 10.1182/blood.2019004126. Blood. 2020. PMID: 32157281 Free PMC article.
Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantation.
Prockop S, Doubrovina E, Suser S, Heller G, Barker J, Dahi P, Perales MA, Papadopoulos E, Sauter C, Castro-Malaspina H, Boulad F, Curran KJ, Giralt S, Gyurkocza B, Hsu KC, Jakubowski A, Hanash AM, Kernan NA, Kobos R, Koehne G, Landau H, Ponce D, Spitzer B, Young JW, Behr G, Dunphy M, Haque S, Teruya-Feldstein J, Arcila M, Moung C, Hsu S, Hasan A, O'Reilly RJ. Prockop S, et al. Among authors: doubrovina e. J Clin Invest. 2020 Feb 3;130(2):733-747. doi: 10.1172/JCI121127. J Clin Invest. 2020. PMID: 31689242 Free PMC article. Clinical Trial.
Adoptive immunotherapy with haploidentical natural killer cells and Anti-GD2 monoclonal antibody m3F8 for resistant neuroblastoma: Results of a phase I study.
Modak S, Le Luduec JB, Cheung IY, Goldman DA, Ostrovnaya I, Doubrovina E, Basu E, Kushner BH, Kramer K, Roberts SS, O'Reilly RJ, Cheung NV, Hsu KC. Modak S, et al. Among authors: doubrovina e. Oncoimmunology. 2018 May 10;7(8):e1461305. doi: 10.1080/2162402X.2018.1461305. eCollection 2018. Oncoimmunology. 2018. PMID: 30221057 Free PMC article.
33 results